In June, we added 93 citations in DIDB, including 48 in vitro (with 16 articles published in June 2024) and 45 in vivo articles (with 41 articles published in June 2024).
3 NDAs approved in 2024, including ceftobiprole (ZEVTERA), danicopan (VOYDEYA), and mavorixafor (XOLREMDI), were also curated in DIDB.
You can check the citations that are recently published and entered in DIDB and all the NDAs/BLAs in DIDB.
As always, feel free to contact us if you have any questions or comments.